A 38-year-old woman from Kerala completes concurrent chemoradiotherapy (70 Gy EBRT + 3 cycles cisplatin) for Stage IIIA nasopharyngeal carcinoma 8 weeks ago. Post-treatment MRI shows a 2 cm residual mass in the nasopharynx with no distant metastasis. She is asymptomatic and tolerating oral intake well. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has completed concurrent chemoradiotherapy for locally advanced NPC and has a residual mass on imaging 8 weeks post-treatment. The timing and size of the residual lesion are critical to management decisions. ## Post-Treatment Response Assessment Timeline **Key Point:** Residual masses on imaging 8–12 weeks after completion of chemoradiotherapy do NOT automatically indicate treatment failure. Radiation-induced edema, fibrosis, and necrotic tumor can persist and may resolve over 3–6 months. **High-Yield:** Current guidelines recommend delaying salvage surgery or further intervention until at least 12 weeks post-treatment to allow complete assessment of treatment response. Early imaging (< 8 weeks) often overestimates residual disease. ## Management Algorithm for Residual Disease ```mermaid flowchart TD A[Post-CCRT residual mass on imaging]:::outcome --> B{Time since CCRT completion?}:::decision B -->|< 8 weeks| C[Defer imaging; counsel on expected edema]:::action B -->|8-12 weeks| D[Repeat MRI/PET-CT to assess response]:::action D --> E{Complete response?}:::decision E -->|Yes| F[Surveillance: MRI/endoscopy q3m × 2y]:::action E -->|No: Residual disease| G{Size & feasibility?}:::decision G -->|Small, accessible| H[Salvage nasopharyngectomy or brachytherapy]:::action G -->|Large or unresectable| I[Palliative chemotherapy]:::action B -->|> 12 weeks| D ``` ## Rationale for Repeat Imaging at 8–12 Weeks 1. **Radiation effects resolve slowly:** Edema and inflammation peak at 4–8 weeks and gradually regress over 3–6 months. 2. **Tumor necrosis mimics residual disease:** Dead tumor tissue may appear as a mass on MRI but represents treatment success. 3. **Avoid unnecessary salvage surgery:** Premature intervention in responding patients increases morbidity without benefit. 4. **PET-CT is superior at this timepoint:** FDG-PET can differentiate viable tumor (high uptake) from necrotic/fibrotic tissue (low uptake). **Clinical Pearl:** If repeat imaging at 12 weeks shows complete response (CR), surveillance with flexible nasopharyngoscopy and MRI every 3 months for 2 years is standard. If residual disease persists and is resectable, salvage nasopharyngectomy or brachytherapy boost is considered. **Warning:** Do NOT perform salvage surgery at 8 weeks based on residual imaging alone — this leads to unnecessary morbidity. Wait for metabolic imaging (PET-CT) or clinical/endoscopic evidence of viable disease.